215 related articles for article (PubMed ID: 23436267)
21. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Chen J; Liu D; Zheng X; Zhao Q; Jiang J; Hu P
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):857-68. PubMed ID: 25850339
[TBL] [Abstract][Full Text] [Related]
22. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Clin Pharmacol Drug Dev; 2014 May; 3(3):194-201. PubMed ID: 27128609
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
[TBL] [Abstract][Full Text] [Related]
24. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
Shi JG; Chen X; Emm T; Scherle PA; McGee RF; Lo Y; Landman RR; McKeever EG; Punwani NG; Williams WV; Yeleswaram S
J Clin Pharmacol; 2012 Jun; 52(6):809-18. PubMed ID: 21602517
[TBL] [Abstract][Full Text] [Related]
25. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
[TBL] [Abstract][Full Text] [Related]
26. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
27. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
28. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
29. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Li J; Kankam M; Trone D; Gammon G
Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
31. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
32. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Deeken JF; Beumer JH; Anders NM; Wanjiku T; Rusnak M; Rudek MA
Cancer Chemother Pharmacol; 2015 Oct; 76(4):813-9. PubMed ID: 26330331
[TBL] [Abstract][Full Text] [Related]
33. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
34. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers.
Ridtitid W; Ratsamemonthon K; Mahatthanatrakul W; Wongnawa M
J Clin Pharm Ther; 2007 Dec; 32(6):585-93. PubMed ID: 18021336
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.
Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
Br J Clin Pharmacol; 2011 Apr; 71(4):522-7. PubMed ID: 21395644
[TBL] [Abstract][Full Text] [Related]
37. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
Rakhit A; Pantze MP; Fettner S; Jones HM; Charoin JE; Riek M; Lum BL; Hamilton M
Eur J Clin Pharmacol; 2008 Jan; 64(1):31-41. PubMed ID: 18000659
[TBL] [Abstract][Full Text] [Related]
38. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
[TBL] [Abstract][Full Text] [Related]
39. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
Choi JS; Choi I; Choi DH
Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
[TBL] [Abstract][Full Text] [Related]
40. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
